|
rs387907272
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In a case-control study, 100 patients with CLL and 105 healthy individuals were investigated for Notch homolog 1, translocation-associated (<i>Drosophila</i>) (NOTCH1) c.7544-7545delCT, recombinant splicing factor 3B subunit 1 (SF3B1) c.2098A>G, mouse double minute 2 homolog (MDM2) 40-bp insertion/deletion and myeloid differentiation primary response 88 (MYD88) L265P mutations by using allele specific-polymerase chain reaction (AS-PCR), a designed AS-PCR, PCR and PCR-restriction fragment length polymorphism methods, respectively.
|
30930998 |
2019 |
|
rs387907272
|
|
|
0.080 |
GeneticVariation |
BEFREE |
To determine whether MYD88 L265P mutations can be therapeutically exploited in CLL, we treated primary cells with an inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), a critical effector of the MYD88 pathway.
|
30537114 |
2019 |
|
rs387907272
|
|
|
0.080 |
GeneticVariation |
BEFREE |
A plasmid with an MYD88-L265P mutation was constructed, and the p.L265P substitution, which is the predominant <i>MYD88</i> mutation in CLL, was detected using HRM analysis and direct sequencing.
|
31289558 |
2019 |
|
rs387907272
|
|
|
0.080 |
GeneticVariation |
BEFREE |
We identified the L265P hotspot mutation in 86% (n=67/78) of our LPL and 2% (n=12/767) of our CLL cohort.
|
27840426 |
2017 |
|
rs387907272
|
|
|
0.080 |
GeneticVariation |
BEFREE |
MYD88 L265P was found in 49/51 (96%) LPL cases and in 1/13 (7·6%) MZL (splenic type), whereas all CLL samples remained negative.
|
25819228 |
2015 |
|
rs387907272
|
|
|
0.080 |
GeneticVariation |
BEFREE |
MYD88 L265P mutation has been reported in ∼90% of Waldenström's Macroglobulinemia (WM) patients and immunoglobulin M (IgM) monoclonal gammopathies of uncertain significance (MGUS), as well as in some cases of lymphoma and chronic lymphocytic leukemia.
|
24992174 |
2015 |
|
rs387907272
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Thus, pyrosequencing for the MYD88 L265P mutation demonstrates a high clinical sensitivity and specificity to distinguish LPL from MZL and CLL.
|
26230596 |
2015 |
|
rs387907272
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Recurrent L265P mutation of myeloid differentiation primary response gene 88 (MYD88) has been identified in a proportion of diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia.
|
23178471 |
2013 |